Filament Health OTCPK:FLHL.F Lagerbericht Finanzdaten des Unternehmens
Filament Health Corp.
OTCPK:FLHL.F Lagerbericht
Marktkapitalisierung: US$8.4m
FLHL.F Aktienübersicht Filament Health Corp. ist ein kanadisches Unternehmen, das natürliche psychedelische Arzneimittel in der klinischen Phase entwickelt.
Belohnungen Risikoanalyse + 2 mehr Risiken
Alle Risikoprüfungen anzeigen Filament Health Corp. Wettbewerber Preisentwicklung & Leistung
Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Filament Health Historische Aktienkurse Aktueller Aktienkurs US$0.04 52-Wochen-Hoch US$0.15 52-Wochen-Tief US$0.021 Beta 1 11 Monat Veränderung 15.84% 3 Monate Veränderung -15.05% 1 Jahr Veränderung -55.67% 33 Jahre Veränderung -84.81% 5 Jahre Veränderung n/a Veränderung seit IPO -86.86%
Aktuelle Nachrichten und Updates Filament Health Corp. announced that it has received CAD 1 million in funding from Negev Capital Jun 14
Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder
Filament Health Corp. Announces Change to Board of Directors May 06 Filament Health Corp. Announces Chief Financial Officer Changes
Filament Health Corp. Completes the First Export of Botanical Psilocybin to Israel Feb 15
Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders Jan 31 Weitere Updates anzeigen Filament Health Corp. announced that it has received CAD 1 million in funding from Negev Capital Jun 14
Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder
Filament Health Corp. Announces Change to Board of Directors May 06 Filament Health Corp. Announces Chief Financial Officer Changes
Filament Health Corp. Completes the First Export of Botanical Psilocybin to Israel Feb 15
Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders Jan 31 Filament Health Corp. announced that it has received CAD 0.9 million in funding from Negev Capital Dec 07
Filament Health Announces Health Canada Authorization for Phase 2 Clinical Trial Studying Botanical Psilocybin for Opioid Use Disorder Oct 11 Filament Health Corp. announced that it expects to receive CAD 2 million in funding from Negev Capital Oct 01
Filament Health Corp., Annual General Meeting, Nov 07, 2023 Sep 26
Filament Health Corp. Announces FDA Approval of Two Clinical Trials Studying Its Biological Psychedelic Drug Candidate PEX010 Aug 09 Filament Health Corp. announced that it has received CAD 2.5 million in funding from Negev Capital Jul 25
Filament Health Announces Clinical Trial Approval in Partnership with Psychiatric Centre Copenhagen Jan 19
Filament Health Corp. Announces Change to Board of Directors Dec 31
Filament Health Corp. and Atma Journey Centers Inc. Announce 14 Subjects Dosed in Health Canada-Approved Psilocybin Clinical Trial Sep 02
Filament Health Corp. Announces the Appointment of Dr. Konstantin Adamsky to Board of Directors, and Jeff Chilton of Nammex to the Advisory Council Aug 25
Filament Health Corp. Announces Eighth Patent Issuance Aug 18 Filament Health Corp. announced that it has received CAD 2.50008 million in funding from North American Medicinal Mushroom Extracts, Negev Capital Jul 14
Filament Health Corp. Receives Third Patent by United States Patent and Trademark Office Jul 13
Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial Jul 08
Filament Health Announces Sixth Patent Issuance Jul 07 Filament Health Corp. announced that it expects to receive CAD 2.50008 million in funding from North American Medicinal Mushroom Extracts, Negev Capital Jul 01
Filament Health Corp. Announces Patient Dosing Through Health Canada Special Access Program Jun 17
Filament Health Corp. Cultivates 70th Variety of Psilocybin-containing Mushrooms At Its 3,500 Square Foot Gmpcompliant Facility in Metro Vancouver Jun 11
Filament Health Corp. Issues Second Patent by United States Patent and Trademark Office May 19
Filament Health Corp., Annual General Meeting, Jun 28, 2022 May 07
Filament Health Corp. and Cybin Therapeutics Announce Approval for Phase Ii Clinical Trial for Depression Feb 01
Filament Health Corp. Announces Health Canada Approval for Phase II Clinical Trial Administering New Psilocybin Microdose Formulation Jan 05 Aktionärsrenditen FLHL.F US Pharmaceuticals US Markt 7D -4.4% 1.1% 5.7% 1Y -55.7% 16.6% 36.9%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: FLHL.F unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 16.6% erzielte.
Rendite vs. Markt: FLHL.F hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 36.9 erzielte.
Preisvolatilität Is FLHL.F's price volatile compared to industry and market? FLHL.F volatility FLHL.F Average Weekly Movement 38.9% Pharmaceuticals Industry Average Movement 9.4% Market Average Movement 6.2% 10% most volatile stocks in US Market 15.3% 10% least volatile stocks in US Market 3.0%
Stabiler Aktienkurs: FLHL.FDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.
Volatilität im Zeitverlauf: FLHL.FDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 33% auf 39% gestiegen.
Über das Unternehmen Filament Health Corp. ist ein kanadisches Unternehmen, das natürliche psychedelische Arzneimittel in der klinischen Phase entwickelt. Seine führenden Arzneimittelkandidaten sind PEX010 orales Psilocybin, PEX020 orales Psilocin und PEX030 sublinguales Psilocin. Das Unternehmen entwickelt auch AEX010 Ayahuasca, das sich in der präklinischen Phase befindet, und AEX020, einen Monoaminoxidase-Hemmer, der sich ebenfalls in der präklinischen Phase befindet.
Mehr anzeigen Filament Health Corp.'s Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Filament Health im Vergleich zum Marktanteil des Unternehmens? FLHL.F grundlegende Statistiken Marktanteil US$8.44m Gewinn(TTM ) -US$3.22m Umsatz(TTM ) US$1.78m
5.8x Kurs-Umsatz-Verhältnis
-3.2x Kurs-Gewinn-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) FLHL.F Gewinn- und Verlustrechnung (TTM ) Einnahmen CA$2.48m Kosten der Einnahmen CA$0 Bruttogewinn CA$2.48m Sonstige Ausgaben CA$6.96m Umsatz -CA$4.48m
Zuletzt gemeldete Gewinne
Jun 30, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) -0.017 Bruttomarge 100.00% Nettogewinnspanne -181.08% Schulden/Eigenkapital-Verhältnis 0%
Wie hat sich FLHL.F auf lange Sicht entwickelt?
Historische Performance und Vergleiche
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
